Hong Kong's stock market value rankings are fresh, the pharmaceutical company's ranking changes deserve attention

"Pharmaceutical Network Industry Dynamics" As of August 26, 2020, a new market capitalization ranking of Hong Kong stocks has been released.
from the top 50 list, the change in the ranking of Pharmaceutical Life is very obvious, from the original 36 to 29, up seven places, the current market value of HK$255.851 billion.
on August 27th, the stock rose more than 6 per cent to a record high.
Pharmaceuticals announced interim results on August 17th, reporting revenue of 1,944 million yuan in the first half of this year, up 21% year-on-year, while profit attributable to shareholders increased 63.6% year-on-year to 736 million yuan, with no dividends.
regions, the revenues of Medicinal Organisms in North America, China, Europe and the rest of the world were RMB878 million, RMB 816 million, RMB123 million and RMB128 million, respectively, during the reporting period. Business revenue growth in all regions was 3.7%, 43.3%, 9.2% and 61.6%, respectively, corresponding to 45.2%, 42%, 6.3% and 6.5% of total revenue.
attributed the increase mainly to the immediate and effective implementation of the Business Continuity Program to minimize the impact of public health events on its business and operations, the increased utilization of existing bases, resulting in strong growth in development and production revenues, and the addition of more customer projects to the Group's research and development pipeline to accelerate the development and production of potential therapies related to public health events to support its global customers.
the first half of this year, the company's research and development spending increased by 14.0% to $124 million, mainly due to the company's increased investment in innovation and technology to enhance the Group's core competitiveness in an evolving industry.
data show that in the first half of 2020, the number of pharmaceutical-based bio-integrated projects reached 286, up 27.7% from 224 in the same period in 2019, and the number of preclinical projects reached 33, up 141% from 106 in the same period in 2019.
As of June 30, 2020, the number of early clinical development projects (Phase I. and II. ) had increased from 102 in the same period last year to 125, the number of late clinical (Phase III. ) projects had increased from 15 in the same period last year to 19, and 12 projects had progressed from the preclinical development phase to the early clinical development phase.
recent years, the good news for medicinal organisms has been constant.
For example, on August 11th, Pharmaceutical Life received an increase of 2251, 000 shares from JPMorgan Chase, involving about HK$36,959,000, and Damore raised its target price from HK$130.6 to HK$210, maintaining its "overweight" rating and raising its earnings forecast for 2022-2024 by 7%, 22% and 46%, respectively.
on the evening of August 14th, Pharmaceuticals was announced to be included in the Hang Seng Index with a weighting of 1.75 per cent; Reiterate its "buy" rating, raising its target price from HK$193.9 to HK$220.91, while Credit Raith raised its target price from HK$159.6 to HK$195.3, maintaining a "outse-of-the-market" rating.
public information shows that Pharmaceuticals is an open, integrated biopharmaceutical capability and technology empowerment platform across the world.
its research and development and production service platform covers a wide range of biological drugs, in addition to traditional monoantigens, including more complex fusion proteins, dual antibodies, ADC antibody conceded drugs, enzymes and so on.
provides end-to-end research and development services to biopharmaceutical and biotechnology companies worldwide, helping anyone, any company, discover, develop and produce biopharmaceuticals, accelerate the global biopharmaceutical research and development process, and reduce research and development costs.
75.6 per cent of China's bio-research and development outsourcing services sector in 2018 and 3.2 per cent globally, according to Contract Pharma, a research and development firm.
industry believes that as the domestic biopharmaceous drug research and development and production outsourcing (CDMO) industry enters a golden period, Pharmaceuticals will use its obvious industry advantage position to ensure continued high performance growth.